# Electrochemical Skin Conductance Alterations during Spinal Cord Stimulation: An Experimental Study

Lisa Goudman, Nieke Vets, Julie Jansen, Ann de Smedt, Maxime Billot, Philippe Rigoard, Ann Cordenier, Sebastiaan Engelborghs, Aldo Scafoglieri, Maarten Moens

► To cite this version:

Lisa Goudman, Nieke Vets, Julie Jansen, Ann de Smedt, Maxime Billot, et al.. Electrochemical Skin Conductance Alterations during Spinal Cord Stimulation: An Experimental Study. Journal of Clinical Medicine, 2021, 10 (16), pp.3565. 10.3390/jcm10163565. hal-04217752

HAL Id: hal-04217752

https://hal.science/hal-04217752v1

Submitted on 26 Sep 2023

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons CC BY 4.0 - Attribution - International License
Article

# Electrochemical Skin Conductance Alterations during Spinal Cord Stimulation: An Experimental Study

Lisa Goudman<sup>1,2,3,4,*</sup>, Nieke Vets<sup>1,2</sup>, Julie Jansen<sup>1,2</sup>, Ann De Smedt<sup>2,3,5</sup>, Maxime Billot<sup>6</sup>,
Philippe Rigoard<sup>6,7,8</sup>, Ann Cordenier<sup>3,9</sup>, Sebastiaan Engelborghs<sup>3,9,10</sup>, Aldo Scafoglieri<sup>11</sup>
and Maarten Moens<sup>1,2,3,4,12</sup>

<figure><img src="image_2.png" /></figure>

check for
updates

**Citation:** Goudman, L.; Vets, N.; Jansen, J.; De Smedt, A.; Billot, M.; Rigoard, P.; Cordenier, A.; Engelborghs, S.; Scafoglieri, A.; Moens, M. Electrochemical Skin Conductance Alterations during Spinal Cord Stimulation: An Experimental Study. *J. Clin. Med.* **2021**, *10*, 3565. https://doi.org/10.3390/jcm10163565

Academic Editor: Hiroyuki Katoh

Received: 25 July 2021

Accepted: 11 August 2021

Published: 13 August 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

<figure><img src="image_3.png" /></figure>

**Copyright:** © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

**Abstract:** Despite the well-known clinical effects of spinal cord stimulation (SCS), the mechanisms of action have not yet been fully unraveled. The primary aim of this study was to measure whether electrochemical skin conductance, as a measure of peripheral sympathetic autonomic function, is altered by SCS. A second aim was to compare skin conductance levels of patients with failed back surgery syndrome (FBSS) with age- and sex-matched healthy controls. Twenty-three patients with FBSS treated with SCS participated in this study. Sudomotor function was measured with the SudoscanTM instrument on the hands and feet during SCS on and off states. Difference scores in skin conductance between patients and age- and sex-matched healthy controls were calculated. Normal sudomotor function at the painful lower limb was revealed for 61% of the patients when SCS was activated. Skin conductance levels were not altered between on and off states of SCS. Differences in scores between patients and healthy controls were significantly different from zero. This study showed that SCS does not influencing the sympathetic nervous system in patients with FBSS, as measured by skin conductance levels. Moreover, it suggested that there is no normalization of the functioning of the sympathetic nervous system, despite the effectiveness of SCS to reduce pain intensity.

**Keywords:** autonomic nervous system; electrodermal activity; neuromodulation; chronic pain

## 1. Introduction

In many patients with failed back surgery syndrome (FBSS), the origin of the persisting element in the pain experience is still unknown, which makes targeted treatment difficult

<footnote n="1">1 Department of Neurosurgery, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium; Nieke.Vets@uzbrussel.be (N.V.); Julie.Jansen@uzbrussel.be (J.J.); Maarten.Moens@uzbrussel.be (M.M.)</footnote>

<footnote n="2">2 Stimulus Consortium (Research and Teaching Neuromodulation Uz Brussel), Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium; Ann.DeSmedt@uzbrussel.be</footnote>

<footnote n="3">3 Center for Neurosciences (C4N), Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium; Ann.Cordenier@uzbrussel.be (A.C.); sebastiaan.engelborghs@uzbrussel.be (S.E.)</footnote>

<footnote n="4">4 Pain in Motion International Research Group, Laarbeeklaan 103, 1090 Brussels, Belgium</footnote>

<footnote n="5">5 Department of Physical Medicine and Rehabilitation, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium</footnote>

<footnote n="6">6 Prismatics Lab (Predictive Research in Spine/Neuromodulation Management and Thoracic Innovation/Cardiac Surgery), Poitiers University Hospital, 86021 Poitiers, France; Maxime.BILLOT@chu-poitiers.fr (M.B.); Philippe.RIGOARD@chu-poitiers.fr (P.R.)</footnote>

<footnote n="7">7 Department of Spine, Neuromodulation and Rehabilitation, Poitiers University Hospital, 86021 Poitiers, France</footnote>

<footnote n="8">8 Institut Pprime UPR 3346, CNRS, ISAE-ENSMA, University of Poitiers, 86360 Chasseneuil-du-Poitou, France</footnote>

<footnote n="9">9 Department of Neurology, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium</footnote>

<footnote n="10">10 Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Universiteitsplein 1, 2610 Antwerp, Belgium</footnote>

<footnote n="11">11 Experimental Anatomy Research Department, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium; Aldo.Scafoglieri@vub.be</footnote>

<footnote n="12">12 Department of Radiology, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium</footnote>

<footnote>* Correspondence: lisa.goudman@uzbrussel.be; Tel.: +32-2477-5514</footnote>
to deliver [1,2]. Spinal cord stimulation (SCS) is a well-known treatment option for therapy-
refractory FBSS, with pain-relieving effects as well as positive effects on quality of life,
exercise capacity, anxiety, and depression [3–9]. Nevertheless, the exact mechanisms of SCS
are not yet fully understood [10]. Since the late 1960s, with the introduction of the pain gate
control theory [11], several complementary hypotheses based on spinal, segmental, and
supraspinal elements have been proposed [12,13]. The hypotheses that have gained a lot of
attention are the supraspinal mechanisms with modulations of the descending nociceptive
inhibitory pathways [14], the ascending medial pathway [15], and the ascending lateral
pathway [16,17]. More recent research has pointed towards the involvement of glial
cells [18,19], gene expression [20], and local tissue temperature increases [21]. Another
hypothesis is the influence of the autonomic nervous system in chronic neuropathic pain
and the possible target focus on this part of the nervous system by SCS [22].

In healthy individuals, a dynamic balance between the excitatory sympathetic part and inhibitory parasympathetic part of the autonomic nervous system is present [23,24]. In chronic pain patients, dysregulation of the autonomic nervous system has been revealed, with a lower parasympathetic contribution compared to healthy controls [25,26]. These conclusions were based on analyses of heart rate variability, whereby high frequency oscillations can be denoted as mediated through the vagus nerve [27]. Previously, it was suggested that low-frequency oscillations represent a combination of sympathetic and vagal activity [28]; however, low-frequency power can also denote a measure of modulation of the cardiac autonomic outflow by baroreflexes and not a measure of cardiac sympathetic tone [29,30]. As such, there is a need for a more direct evaluation of the sympathetic nervous system.

Sudorimetry, i.e., measuring the function of sweat gland innervation, specifically
evaluates the peripheral sympathetic system [31]. In contrast to quantitative sudomotor
axon reflex tests or skin biopsies, the SudoscanTM is a simple, non-invasive sudomotor
test that allows measurement of the sweat gland function [32]. It is easy to perform,
has a good reproducibility [33,34], can be rapidly conducted, and is very well tolerated
(i.e., not uncomfortable), which are crucial aspects to implement this technique in clinical
practice [35]. This method is based on the electrochemical reaction between sweat chlorides
and stainless steel electrodes in contact with the palms and soles [32]. In patients with
diabetes mellitus, it has been denoted as a promising, sensitive tool to detect diabetic
neuropathy, with proven diagnostic performance and usefulness to monitor treatment
efficacy [34–36]. Currently, the SudoscanTM is used in a broad range of populations,
including patients with COVID-19 [37], multiple system atrophy [38], and Parkinson’s
disease [39].

The goal of this study was to further unravel the mechanisms of action of SCS by
evaluating whether SCS can influence the peripheral sympathetic nervous system; therefore,
the first aim was to measure whether electrochemical skin conductance, as measured with
the SudoscanTM, is altered by SCS in patients suffering from FBSS. A second aim was
to compare skin conductance of patients with FBSS who receive SCS to an age- and sex-
adjusted normal population.

**2. Materials and Methods**

2.1. *Participants*

Patients with FBSS who received treatment with SCS at the department of Neurosurgery of Universitair Ziekenhuis Brussels were invited to participate in this study. According to routine clinical care at our center (and regulated by reimbursement rules), all patients had a standard clinical visit regarding their treatment progress every 6 months. Selection of patients was based on those FBSS patients who were scheduled for a 6 month SCS follow-up visit. Patients were allowed to take part in this study if they were at least 18 years old. Patients were not allowed to take part in the study if they had impaired skin integrity at the fingers and feet or if they had been previously diagnosed with major psychiatric problems.
The study protocol was approved by the central ethics committee of Universitair Ziekenhuis Brussels (B.U.N. 1432020000073) on 27 May 2020. The study was registered on [clinicaltrials.gov](https:// clinicaltrials.gov) (NCT04668482). All patients provided written informed consent before participation. The study was conducted according to the revised Declaration of Helsinki (1998).

## 2.2. Protocol

This was an experimental study, consisting of a single outpatient visit. All patients who took part in this study were instructed to switch off SCS 12 h before their study visit. During the study visit, skin conductance was first recorded when SCS was still switched off. Afterwards, patients were asked to provide a pain intensity score. After this measurement, patients had to switch their neurostimulator on, followed by a rest period of 30 min. A second evaluation of skin conductance and pain intensity reporting was conducted after this 30 min break. Due to the pain-relieving effects of SCS, patients could not be blinded to the study conditions.

All patients were asked to confirm that they switched off SCS 12 h before the study visit. This statement was controlled by evaluating whether SCS was effectively switched off (which was the case for all patients) when patients presented themselves for the study visit.

## 2.3. Self-Reported Outcome Measurements

To assess the current pain intensity, the visual analogue scale (VAS) was used for lower back pain and leg pain separately. For the VAS, a 10 cm line on paper was provided to all patients, representing a continuum between no pain and maximal pain. Pain intensity is expressed here in mm on a scale from 0 to 100. Patients completed this questionnaire twice; once when SCS was switched off and once when SCS was activated. The VAS pain score is a reliable and valid tool that is sensitive to change [40–43].

The Medication Quantification Scale III (MQS) was used to quantify and monitor different drug regimens used to treat a variety of pain conditions [44]. This tool uses a numerical representation of the negative impact each medication has in treating a patient’s pain [45].

## 2.4. Sudomotor Function

The Sudoscan™ (Impeto Medical, Paris, France) evaluates sudomotor function through the measurement of electrochemical skin conductance (ESC) using reverse iontophoresis and chronoamperometry [46]. It reflects the sudomotor skin reactivity, since sweat glands on the hands and feet are innervated by postglandionic unmyelinated sudomotor cholinergic sympathetic C-fibers [37]. As such, it provides an indication of the peripheral sympathetic autonomic function [47]. This is a non-invasive method based on an electrochemical reaction between sweat chloride and stainless steel electrodes after stimulation of the sweat glands by a low voltage direct current (<4 V) [37]. At low voltages (<10 V), the stratum corneum is electrically insulating, and only sweat gland ducts are conductive [47]. During the examination, patients were asked to stand with the palms of their hands and soles of their feet in contact with the electrodes for 2–3 min. Electrochemical skin conductance is expressed here in microsiemens (µS) and was derived from the ratio between measured current and the applied voltage [37]. According to previously defined thresholds for Caucasians, >60 µS represents normal sudomotor function, 40–60 µS a moderate sudomotor dysfunction, and <40 µS a sudomotor severe dysfunction for ESC measured at the hands, while cut-off values of >70 µS, 50–70 µS, and <50 µS are applied for ESC at the feet, respectively [31]. All measurements took place in the same room to limit the influence of environmental factors. Patients were allowed 10 min to adjust before the start of the measurements to ensure all patients were feeling comfortable in the measurement room.
## 2.5. Reference Data

Reference data for ESC were taken from the study by Vinik et al. (2016), in which data from 1350 healthy study participants were collected and analyzed [48]. The selected normal data were stratified by age category, sex, and measurement location (hands or feet), which allowed matching with our study population.

## 2.6. Sample Size Calculation

Sample size calculation was performed using G*Power 3.1.3 (Düsseldorf, Germany) based on the sympathetic skin response of healthy controls versus patients with chronic lower back pain and FBSS [49]. Mean amplitude (mv) values of 5.27 (SD 2.47) for patients and 6.65 (SD 0.84) for healthy controls were used in the current calculation. The minimal total sample size for a Wilcoxon test with matched pairs should reach 20 patients, based on two-tailed testing with $\alpha = 0.05$, a desired power of 0.85, and a correlation of 0.8 between the two conditions.

## 2.7. Statistical Analysis

All analyses were performed in R Studio version 1.2.5019 (R version 3.6), except for the mixed models, which were constructed with SAS version 9.4. Here, *p*-values of 0.05 or less were considered statistically significant. No missing data were observed, meaning there was no need for imputation strategies. Normality was evaluated with the Shapiro-Wilk test and QQ-plots, while equality of variance was evaluated with Levene's tests. Descriptive statistics are provided as means (±SD) or as medians (first and third quartile). A simple regression model was built with pain intensity scores as the outcome variables and the on and off states of SCS and pain location (low back or leg) as explanatory variables using an automatic step function.

ESC values between SCS on and off states were compared with Wilcoxon tests for hands and feet separately. Additionally, mixed models were constructed with ESC values as outcome variables and SCS condition, age, MQS score, and pain intensity scores as exploratory variables. Individual difference scores between patients and age- and sex-matched healthy persons were calculated by subtracting the score of the matched control from the patient score. A negative difference score indicated that the patient score was lower than the score of the matched control. Single-sample Wilcoxon tests were applied to evaluate whether the difference scores were significantly different from zero.

# 3. Results

## 3.1. Descriptive Statistics

In total, 23 patients were included in this study. All experiments were conducted on 12 December 2020. Twelve males and 11 females took part in this study. Patients had a mean age of 55.0 (SD: 9.2) years and a median BMI of 27 (Q1-Q3: 26.0-29.5) kg/m². The median duration that patients were implanted with SCS was 3 (Q1-Q3: 2-7) years. The median score on the MQS was 11 (Q1-Q3: 6.2-16.1). All patients were Caucasians.

Figure 1 presents boxplots with observed data points for pain intensity scores for lower back and leg pain separately (i.e., data as observed). A simple regression model for pain intensity scores revealed a significant effect of SCS condition (type III test: $F = 20.32, p < 0.001$) on pain intensity. The expected pain intensity score (i.e., based on the regression model) for a patient with FBSS when SCS was deactivated was 56.67 (95% CI from 48.89 to 64.46). When SCS was activated, the expected pain intensity score was 24.98 (95% CI from 13.97 to 35.99). Pain location (lower back or leg) was not withheld in the final model (type III test: $F = 0.009, p = 0.92$).

Additionally, 23 healthy controls were matched to the patients in our study population based on sex and age category.
<figure><img src="image_4.png" /><figcaption>**Figure 1.** Boxplots showing individual observations of the pain intensity scores during SCS off and SCS on states for lower back (**left**) and leg pain (**right**). The first box presents the pain intensity scores during the SCS off state and the second box during the SCS on state. Abbreviations. OFF: SCS switched off; ON: SCS switched on; SCS: spinal cord stimulation.</figcaption></figure>

## 3.2. Electrochemical Skin Conductance

The median ESC values did not significantly differ between SCS on and off states for measurements of the painful lower limb (V = 153.5, *p* = 0.19), non-painful lower limb (V = 114.5, *p* = 0.44), upper limb on the painful side (V = 147.5, *p* = 0.78), or upper limb on the non-painful side (V = 151, *p* = 0.70). The results of these measurements are presented in Table 1.

<table><caption>**Table 1.** Electrochemical skin conductance values (expressed in µS) obtained during SCS on and off conditions for patients with FBSS. Data are expressed as medians with Q1 and Q3. OFF: SCS switched off; ON: SCS switched on; SCS: spinal cord stimulation.</caption><thead><tr><th>Location</th><th>SCS Off</th><th>SCS On</th><th>Test Statistic Wilcoxon Test</th></tr></thead><tbody><tr><td>Foot, painful side</td><td>82.00<br>(Q1-Q3: 67.0-85.5)</td><td>75.00<br>(Q1-Q3: 64.5-84.5)</td><td>V = 153.5, p = 0.19</td></tr><tr><td>Foot, non-painful side</td><td>75.00<br>(Q1-Q3: 65.5-85.0)</td><td>70.00<br>(Q1-Q3: 59.0-85.5)</td><td>V = 114.5, p = 0.44</td></tr><tr><td>Hand, painful side</td><td>70.00<br>(Q1-Q3: 52.5-78.0)</td><td>62.00<br>(Q1-Q3: 55.0-78.5)</td><td>V = 147.5, p = 0.78</td></tr><tr><td>Hand, non-painful side</td><td>71.00<br>(Q1-Q3: 51.0-80.5)</td><td>62.00<br>(Q1-Q3: 52.5-76.5)</td><td>V = 151.0, p = 0.70</td></tr></tbody></table>

Mixed models for ESC on the lower limb on the painful side resulted in a significant effect of SCS condition (type III test F = 4.69, *p* = 0.04). The results of the model are presented in Table 2. Mixed models for ESC at the other locations did not result in significant type III tests.

## 3.3. Differences between Patients and Matched Controls

The median ESC values for healthy controls were 82.70 (Q1-Q3: 81.35-82.90) for the lower limb and 73.80 (Q1-Q3: 73.05-75.50) for the upper limb, based on the data produced by Vinik et al. (2016) [48]. For patients, the median ESC values during SCS on the painful side were 75 (Q1-Q3: 64.50-84.50) for the lower limb and 62.00 (Q1-Q3: 55.00-78.50) for the upper limb. The median differences in ESC between patients during SCS and matched controls were -8.00 (Q1-Q3: -18.00-2.55) at the lower limb and -13.80 (Q1-Q3: -18.45-2.90) at the upper limb. The median difference scores were significantly different from zero for the lower limb (95% CI from -14.70 to -2.00, *p* = 0.009) and upper limb
(95% CI from -15.55 to -2.40, *p* = 0.01). Figure 2 presents ESC values for healthy controls, patients during both SCS conditions, and difference scores.

<table><caption>**Table 2.** Model estimates for electrochemical skin conductance on the lower limb on the painful side. The reference level for sex is male and the reference level for SCS is the SCS off condition. CI: confidence interval; MQS: Medication Quantification Scale III; OFF: SCS switched off; ON: SCS switched on; SCS: spinal cord stimulation; SE: standard error; VAS: visual analogue scale.</caption><thead><tr><th>Explanatory Factor</th><th>Level</th><th>Estimate</th><th>SE</th><th>95% CI</th><th>Type III Test</th></tr></thead><tbody><tr><td>Intercept</td><td></td><td>112.46</td><td>21.49</td><td>67.49 to 157.43</td><td></td></tr><tr><td>Sex</td><td>female</td><td>-8.54</td><td>6.13</td><td>-21.38 to 4.30</td><td>F = 1.94, p = 0.18</td></tr><tr><td>SCS</td><td>on</td><td>-5.66</td><td>2.61</td><td>-11.13 to -0.19</td><td>F = 4.69, p = 0.04</td></tr><tr><td>Age</td><td></td><td>-0.60</td><td>0.37</td><td>-1.38 to 0.18</td><td>F = 2.60, p = 0.12</td></tr><tr><td>MQS score</td><td></td><td>0.44</td><td>0.32</td><td>-0.22 to 1.10</td><td>F = 1.94, p = 0.18</td></tr><tr><td>VAS score low back</td><td></td><td>-0.05</td><td>0.05</td><td>-0.17 to 0.06</td><td>F = 0.90, p = 0.35</td></tr><tr><td>VAS score leg</td><td></td><td>-0.05</td><td>0.05</td><td>-0.16 to 0.06</td><td>F = 0.83, p = 0.37</td></tr></tbody></table>

During SCS, 14 (61%) patients showed normal sudomotor function, 7 (30%) patients presented with moderate sudomotor dysfunction, and 2 (9%) with severe sudomotor dysfunction with ESC recordings of the painful lower limb. Recordings for the hand (painful side) revealed 12 (52%) patients with normal sudomotor function, 10 (44%) with moderate sudomotor dysfunction, and 1 (4%) with severe sudomotor dysfunction during SCS.

<figure><img src="image_5.png" /><figcaption>**Figure 2.** (Upper row) Boxplots of the electrochemical skin conductance values for healthy controls, for patients when SCS is switched off, and for patients when SCS is switched on for the painful side. (Lower row) Difference scores in electrochemical skin conductance for patients in the SCS on condition for healthy controls. For each figure, individual observations are plotted as well. OFF: SCS switched off; ON: SCS switched on; SCS: spinal cord stimulation.</figcaption></figure>

## 4. Discussion

This study aimed to evaluate whether the autonomic nervous system, and more specifically the peripheral sympathetic system, was altered by SCS. By experimentally manipulating SCS conditions (SCS on versus off), the results indicated that skin conductance is not influenced by SCS. Additionally, skin conductance in patients with FBSS who were treated with SCS was compared to that of healthy controls. A statistically significant difference of -8.00 (Q1-Q3: -18.00-2.55) at the lower limb and -13.80 (Q1-Q3: -18.45-2.90) at the upper limb was found between both groups in favor of healthy controls. This indicates that in normal daily situations (SCS activated), the skin conductance of patients with FBSS was still different from the skin conductance of healthy controls, despite the treatment.

Previous evaluations of the functional impairment of non-myelinated postganglionic sudomotor sympathetic fibers in patients with chronic lower back pain and FBSS by measuring sympathetic skin response (SSR) revealed alterations in SSR (i.e., prolonged latency) in patients compared to healthy controls [49]. Prolonged SSR latencies were also found in
another cohort of 29 patients with FBSS compared to healthy controls [50]. Moreover, in a cohort of 20 patients with FBSS, 18 out of 20 patients presented with abnormal neuro-physiological findings compared to healthy controls, of which 35% demonstrated reduced SSR amplitudes in comparison to healthy control values [51]. Similarly, studies using the SudoscanTM to measure ESC indicated lower values in patients with fibromyalgia [52], Fabry disease [32], and psoriatic arthritis [47] compared to healthy controls. The study results indicated that despite providing SCS (a well-known effective treatment for this patient population [53]), ESC values for both lower and upper limbs were significantly different from the values for healthy controls. This suggests that despite treatment, there was no normalization of sudomotor function towards the level of healthy controls, despite the fact that sudorimetry is considered an efficient tool for treatment monitoring [31]. Indeed, the study by Calvet et al., (2013), in which 52 patients with type 1 diabetes and 115 patients with type 2 diabetes were followed for 12 months, indicated that an intensified insulin treatment resulted in improved ESC values [34]. Pain intensity reporting in our study clearly indicated that SCS was able to significantly reduce pain; nevertheless, this was not accompanied by an increase in ESC. It may be hypothesized that ESC values cannot be normalized after a short time period of 30 min (applied wash-in period for SCS in this study) and that longer treatments are needed, under the assumption that SCS improves ESC values.

Conversely, it is also plausible that SCS provided at the thoracic level does not in-
fluence the sympathetic system but only the parasympathetic system. Previous studies
suggested that the presence of chronic pain induces changes in the balance of the autonomic
nervous system [24,54]. Indirect evaluations relying on heart rate variability were sugges-
tive of a reduction in the activity of the inhibitory parasympathetic system in patients with
chronic pain [24]. This imbalance of the autonomic nervous system could be restored by
applying SCS in patients with FBSS, as measured by an increase in high-frequency power
(vagally mediated) during SCS compared to the situation without SCS [55,56]. Moreover,
in a previous study in patients with FBSS, no influence of SCS was revealed based on
skin conductance (measure of sympathetic activity), which was evaluated at the fingers
(i.e., a remote location compared to the painful region) [56]. Additionally, in patients
with chronic refractory angina, a reduction of the low-frequency/high-frequency ratio
based on heart rate variability measurements was found when SCS was turned off [57,58],
which is suggested to be a marker of sympathovagal balance, reflecting the relationship
between sympathetic and parasympathetic components [59]. Instead of relying on indirect
measurements of the functioning of the autonomic nervous system by heart rate variability
recordings or on measurements at a remote region, the current study specifically evaluated
peripheral sympathetic sudomotor activity in the painful region, without an influence
of SCS. This leads to the hypothesis that if SCS is influencing the autonomic nervous
system, it is predominantly inducing an effect on the parasympathetic system leading to
a normalization of the disbalance between the sympathetic and parasympathetic system,
without explicitly altering the functioning of the sympathetic system. A direct evaluation
of the parasympathetic system could test this hypothesis and help us to further unravel
the mechanisms of action of SCS. A review of experimental studies on the mechanisms
behind SCS in vascular diseases proposed that SCS suppresses sympathetic activity to
obtain SCS-induced vasodilation [60], a finding that could be accompanied with an active
stimulation of the parasympathetic system by SCS.

Patients who were included in this study were implanted with SCS for 3 (Q1–Q3: 2–7) years. The initial effectiveness of SCS generally declines over time due to growing tolerance of the central nervous system in around 20–40% of patients [61,62]. If this is the case, SCS system explantation is often performed and a substantial proportion of these explants happens before 2.25 years of SCS treatment [63], the so-called “break even” point for SCS treatment when compared with conventional medical management [64]. Patel et al. (2019) reviewed the reasons for SCS device explantation in a sample of 129 patients who were treated with SCS [65]. The median time to explantation was 20 months (IQR
7.5–45.5 months), with the primary reason being a lack of efficacy (80.6%) [65]. Only patients who had not yet undergone a device explantation were eligible in this study. This indicates that the obtained study results (i.e., no normalization of skin conductance in patients with FBSS compared to healthy controls and no alteration in skin conductance when experimentally manipulating SCS status) are only valid for patients who are still receiving SCS. Similar (negative) results can be expected at shorter time periods, assuming that SCS is not inducing transient effects on the autonomic nervous system. Additionally, it might be expected that the lack of normalization of skin conductance to the level of healthy controls will also be present in patients who have undergone device explantation. Nevertheless, future studies are needed to confirm these hypotheses.

In this study, the Sudoscan™ was used to evaluate sweat gland function by measuring sweat chloride concentrations using reverse iontophoresis and chronoamperometry [47], without the need for wetting of the skin. In general, wetting or occlusion of the skin by the recording electrolyte can significantly influence EDA [66] in the sense that a dry corneum conducts electricity poorly, whereby eventually a premium is placed on surface sweating, whereas conductivity increases with higher degrees of hydration [67] (i.e., different electrical conductivity [68]). Additionally, the role of skin blood flow could be evaluated in relation to skin conductance; especially for ischemic pain, SCS most likely affects skin blood flow [69]. On the other hand, in patients with neuropathic pain, no change in peripheral skin blood flow was revealed due to SCS [70]. Recently, in 12 healthy persons, transcutaneous electrical SCS (non-invasive) was applied at T11–T12 and L1–L2 with evaluations of the skin [71]. A significant increase in skin blood flow was revealed with a proposed crucial role of the mediator nitric oxide [71]. By experimentally manipulating the SCS status, emotional or psychological states could be altered, which might be associated with alterations in skin blood flow [72,73], potentially influencing skin conductance measurements in this study. Finally, exposing the skin, and more specifically the stratum corneum, to high environmental humidity can promote the hydration of the stratum corneum, whereby high humidity exposure increases skin conductance and skin susceptance in healthy participants [74]; therefore, all measurements took place in the same room on the same day to limit the influence of environmental factors on skin conductance.

Previous research studies have already explored the electrochemical behavior of stainless steels (of which the electrodes of the Sudoscan are composed) by mimicking the behavior of electrodes in contact with sweat through stainless steel 304 L and synthetic buffer carbonate solutions containing chloride, lactate, and urea [75]. The results indicated that stainless steel 304 L is a suitable material for the assessment of sudomotor dysfunction due to its high ability to detect deviations in chloride concentration [75]. The sensitivity of stainless steel 304 L to chloride was higher than for nickel, which was previously used in measurement devices, with the disadvantage of a potential allergic reaction in some patients [76].

This study also had some limitations. Due to the longer wash-out period compared to the wash-in period for SCS, patients were not blinded to the stimulation conditions. An objective measurement instrument that does not rely on self-reporting of patients, i.e., Sudoscan™, was used to limit the influence of the lack of blinding. Another limitation of this study is that the ESC data of patients with FBSS were compared with the ESC data from historical healthy controls. Finally, in this study, an experimental manipulation of the SCS status was performed in all patients. Skin conductance responses can be directly altered related to manipulating the device status or by indirect effects, such as increased pain intensity levels or alterations in psychological factors when SCS is switched off. The potential mediating effect of pain intensity or claims of causality cannot be made with the current study design.

## 5. Conclusions

Sudomotor function, as an indicator of peripheral sympathetic autonomic function, is not altered when manipulating SCS conditions in patients with FBSS. Moreover, the elec-
trochemical skin conductance in patients with FBSS who are receiving treatment with SCS is different from skin conductance in healthy controls, indicating a lack of normalization in this population. The current findings lead to the hypothesis that SCS only influences the parasympathetic system, without a direct alteration of the sympathetic system.

**Author Contributions:** Conceptualization, L.G., A.D.S. and M.M.; data curation, L.G., N.V., J.J. and M.M.; formal analysis, L.G. and M.M.; methodology, L.G., A.D.S. and M.M.; writing—original draft, L.G. and M.M.; writing—review and editing, N.V., J.J., A.D.S., M.B., P.R., A.C., S.E. and A.S. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of Universitair Ziekenhuis Brussels (B.U.N. 143202000073) on 27 May 2020.

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** The data presented in this study are available on motivated request from the corresponding author.

**Conflicts of Interest:** Philippe Rigoard serves as a consultant for Boston Scientific, Medtronic, and Abbott. He received research grants from Abbott, Medtronic, and Boston Scientific. Maarten Moens has received speaker fees from Medtronic and Nevro. STIMULUS received research grants from Medtronic. There are no other conflict of interests to declare.

## References

1. Cho, J.H.; Lee, J.H.; Song, K.S.; Hong, J.Y.; Joo, Y.S.; Lee, D.H.; Hwang, C.J.; Lee, C.S. Treatment outcomes for patients with failed back surgery. *Pain Physician* **2017**, *20*, E29-E43. [CrossRef]

2. Amirdelfan, K.; Webster, L.; Poree, L.; Sukul, V.; McRoberts, P. Treatment options for failed back surgery syndrome patients with refractory chronic pain: An evidence based approach. *Spine* **2017**, *42* (Suppl. S14), S41-S52. [CrossRef]

3. Deer, T.R.; Grider, J.S.; Lamer, T.J.; Pope, J.E.; Falowski, S.; Hunter, C.W.; Provenzano, D.A.; Slavin, K.V.; Russo, M.; Carayannopoulos, A.; et al. A systematic literature review of spine neurostimulation therapies for the treatment of pain. *Pain Med.* **2020**, *21*, 1421-1432. [CrossRef]

4. Hofmeister, M.; Memedovich, A.; Brown, S.; Saini, M.; Dowsett, L.E.; Lorenzetti, D.L.; McCarron, T.L.; MacKean, G.; Clement, F. Effectiveness of neurostimulation technologies for the management of chronic pain: A systematic review. *Neuromodulation* **2020**, *23*, 150-157. [CrossRef] [PubMed]

5. Grider, J.S.; Manchikanti, L.; Carayannopoulos, A.; Sharma, M.L.; Balog, C.C.; Harned, M.E.; Grami, V.; Justiz, R.; Nouri, K.H.; Hayek, S.M.; et al. Effectiveness of spinal cord stimulation in chronic spinal pain: A systematic review. *Pain Physician* **2016**, *19*, E33-E54. [CrossRef] [PubMed]

6. Lamer, T.J.; Moeschler, S.M.; Gazelka, H.M.; Hooten, W.M.; Bendel, M.A.; Murad, M.H. Spinal stimulation for the treatment of intractable spine and limb pain: A systematic review of RCTs and meta-analysis. *Mayo Clin. Proc.* **2019**, *94*, 1475-1487. [CrossRef] [PubMed]

7. Corallo, F.; De Salvo, S.; Cannistraci, C.; Lo Buono, V.; Di Cara, M.; Floridia, D.; Cerra, F.; Romeo, L.; Pria, D.; Bramanti, P.; et al. Chronic pain and spinal cord stimulation. *Medicine* **2020**, *99*, e20490. [CrossRef] [PubMed]

8. Corallo, F.; De Salvo, S.; Floridia, D.; Bonanno, L.; Muscara, N.; Cerra, F.; Cannistraci, C.; Di Cara, M.; Lo Buono, V.; Bramanti, P.; et al. Assessment of spinal cord stimulation and radiofrequency: Chronic pain and psychological impact. *Medicine* **2020**, *99*, e18633. [CrossRef]

9. Campos, W.K.; Linhares, M.N.; Sarda, J.; Santos, A.R.S.; Licinio, J.; Quevedo, J.; Lin, K.; Walz, R. Determinants for meaningful clinical improvement of pain and health-related quality of life after spinal cord stimulation for chronic intractable pain. *Neuromodulation* **2019**, *22*, 280-289. [CrossRef]

10. Frey, M.E.; Manchikanti, L.; Benyamin, R.M.; Schultz, D.M.; Smith, H.S.; Cohen, S.P. Spinal cord stimulation for patients with failed back surgery syndrome: A systematic review. *Pain Physician* **2009**, *12*, 379-397. [CrossRef]

11. Melzack, R.; Wall, P.D. Pain mechanisms: A new theory. *Science* **1965**, *150*, 971-979. [CrossRef]

12. Vallejo, R.; Gupta, A.; Cedeno, D.L.; Vallejo, A.; Smith, W.J.; Thomas, S.M.; Benyamin, R.; Kaye, A.D.; Manchikanti, L. Clinical effectiveness and mechanism of action of spinal cord stimulation for treating chronic low back and lower extremity pain: A systematic review. *Curr. Pain Headache Rep.* **2020**, *24*, 70. [CrossRef] [PubMed]

13. Linderoth, B.; Foreman, R.D. Conventional and novel spinal stimulation algorithms: Hypothetical mechanisms of action and comments on outcomes. *Neuromodulation* **2017**, *20*, 525-533. [CrossRef]

14. De Ridder, D.; Vanneste, S. Burst and tonic spinal cord stimulation: Different and common brain mechanisms. *Neuromodulation* **2016**, *19*, 47-59. [CrossRef]
15. Moens, M.; Marien, P.; Brouns, R.; Poelaert, J.; De Smedt, A.; Buyl, R.; Droogmans, S.; Van Schuerbeek, P.; Sunaert, S.; Nuttin, B. Spinal cord stimulation modulates cerebral neurobiology: A proton magnetic resonance spectroscopy study. *Neuroradiology* **2013**, *55*, 1039–1047. [CrossRef]

16. Quindlen-Hotek, J.C.; Kent, A.R.; De Anda, P.; Kartha, S.; Benison, A.M.; Winkelstein, B.A. Changes in neuronal activity in the anterior cingulate cortex and primary somatosensory cortex with nonlinear burst and tonic spinal cord stimulation. *Neuromodulation* **2020**, *23*, 594–604. [CrossRef] [PubMed]

17. Goudman, L.; De Groote, S.; Linderoth, B.; De Smedt, A.; Eldabe, S.; Duarte, R.V.; Moens, M. Exploration of the supraspinal hypotheses about spinal cord stimulation and dorsal root ganglion stimulation: A systematic review. *J. Clin. Med.* **2021**, *10*, 2766. [CrossRef]

18. Vallejo, R.; Bradley, K.; Kapural, L. Spinal cord stimulation in chronic pain: Mode of action. *Spine* **2017**, *42* (Suppl. S14), S53–S60. [CrossRef] [PubMed]

19. Lind, A.L.; Emami Khoonsari, P.; Sjodin, M.; Katila, L.; Wetterhall, M.; Gordh, T.; Kultima, K. Spinal cord stimulation alters protein levels in the cerebrospinal fluid of neuropathic pain patients: A proteomic mass spectrometric analysis. *Neuromodulation* **2016**, *19*, 549–562. [CrossRef] [PubMed]

20. Royds, J.; Conroy, M.J.; Dunne, M.R.; Cassidy, H.; Matallanas, D.; Lysaght, J.; McCrory, C. Examination and characterisation of burst spinal cord stimulation on cerebrospinal fluid cellular and protein constituents in patient responders with chronic neuropathic pain-A Pilot Study. *J. Neuroimmunol.* **2020**, *344*, 577249. [CrossRef]

21. Zannou, A.L.; Khadka, N.; Truong, D.Q.; Zhang, T.; Esteller, R.; Hershey, B.; Bikson, M. Temperature increases by kilohertz frequency spinal cord stimulation. *Brain Stimul.* **2019**, *12*, 62–72. [CrossRef]

22. Kalmar, Z.; Kovacs, N.; Balas, I.; Perlaki, G.; Plozer, E.; Orsi, G.; Altbacker, A.; Schwarcz, A.; Hejjel, L.; Komoly, S.; et al. Effects of spinal cord stimulation on heart rate variability in patients with chronic pain. *Ideggyogy. Szle.* **2013**, *66*, 102–106.

23. Wehrwein, E.A.; Orer, H.S.; Barman, S.M. Overview of the anatomy, physiology and pharmacology of the autonomic nervous system. *Compr. Physiol.* **2016**, *6*, 1239–1278. [CrossRef] [PubMed]

24. Meeus, M.; Goubert, D.; De Backer, F.; Struyf, F.; Hermans, L.; Coppieters, I.; De Wandele, I.; Da Silva, H.; Calders, P. Heart rate variability in patients with fibromyalgia and patients with chronic fatigue syndrome: A systematic review. *Semin. Arthritis Rheum.* **2013**, *43*, 279–287. [CrossRef]

25. Cohen, H.; Neumann, L.; Shore, M.; Amir, M.; Cassuto, Y.; Buskila, D. Autonomic dysfunction in patients with fibromyalgia: Application of power spectral analysis of heart rate variability. *Semin. Arthritis Rheum.* **2000**, *29*, 217–227. [CrossRef]

26. Dogru, M.T.; Aydin, G.; Tosun, A.; Keles, I.; Guneri, M.; Arslan, A.; Ebinc, H.; Orkun, S. Correlations between autonomic dysfunction and circadian changes and arrhythmia prevalence in women with fibromyalgia syndrome. *Anadolu Kardiyol. Derg.* **2009**, *9*, 110–117.

27. Jandackova, V.K.; Scholes, S.; Britton, A.; Steptoe, A. Healthy lifestyle and cardiac vagal modulation over 10 years: Whitehall II cohort study. *J. Am. Heart Assoc.* **2019**, *8*, e012420. [CrossRef]

28. Paso, R.d.G.A.; Langewitz, W.; Mulder, L.J.; van Roon, A.; Duschek, S. The utility of low frequency heart rate variability as an index of sympathetic cardiac tone: A review with emphasis on a reanalysis of previous studies. *Psychophysiology* **2013**, *50*, 477–487. [CrossRef] [PubMed]

29. Goldstein, D.S.; Bentho, O.; Park, M.Y.; Sharabi, Y. Low-frequency power of heart rate variability is not a measure of cardiac sympathetic tone but may be a measure of modulation of cardiac autonomic outflows by baroreflexes. *Exp. Physiol.* **2011**, *96*, 1255–1261. [CrossRef] [PubMed]

30. Rahman, F.; Pechnik, S.; Gross, D.; Sewell, L.; Goldstein, D.S. Low frequency power of heart rate variability reflects baroreflex function, not cardiac sympathetic innervation. *Clin. Auton. Res.* **2011**, *21*, 133–141. [CrossRef] [PubMed]

31. Vinik, A.I.; Nevoret, M.L.; Casellini, C. The new age of sudomotor function testing: A sensitive and specific biomarker for diagnosis, estimation of severity, monitoring progression and regression in response to intervention. *Front. Endocrinol.* **2015**, *6*, 94. [CrossRef] [PubMed]

32. Sahuc, P.; Chiche, L.; Dussol, B.; Pouget, J.; Franques, J. Sudoscan as a noninvasive tool to assess sudomotor dysfunction in patients with Fabry disease: Results from a case-control study. *Ther. Clin. Risk Manag.* **2016**, *12*, 135–138. [CrossRef] [PubMed]

33. Gin, H.; Baudoin, R.; Raffaitin, C.H.; Rigalleau, V.; Gonzalez, C. Non-invasive and quantitative assessment of sudomotor function for peripheral diabetic neuropathy evaluation. *Diabetes Metab.* **2011**, *37*, 527–532. [CrossRef] [PubMed]

34. Calvet, J.H.; Dupin, J.; Winiecki, H.; Schwarz, P.E. Assessment of small fiber neuropathy through a quick, simple and non invasive method in a German diabetes outpatient clinic. *Exp. Clin. Endocrinol. Diabetes* **2013**, *121*, 80–83. [CrossRef]

35. Smith, A.G.; Lessard, M.; Reyna, S.; Doudova, M.; Singleton, J.R. The diagnostic utility of Sudoscan for distal symmetric peripheral neuropathy. *J. Diabetes Complicat.* **2014**, *28*, 511–516. [CrossRef]

36. Casellini, C.M.; Parson, H.K.; Richardson, M.S.; Nevoret, M.L.; Vinik, A.I. Sudoscan, a noninvasive tool for detecting diabetic small fiber neuropathy and autonomic dysfunction. *Diabetes Technol. Ther.* **2013**, *15*, 948–953. [CrossRef]

37. Hinduja, A.; Moutairou, A.; Calvet, J.H. Sudomotor dysfunction in patients recovered from COVID-19. *Neurophysiol. Clin.* **2021**, *51*, 193–196. [CrossRef]

38. Gagaouzova, B.S.; Datema, M.; Thijs, R.D.; Tannemaat, M.R.; Steenmeijer, S.R.; Notting, I.C.; van Dijk, J.G. Can novel non-invasive autonomic tests help discriminate between pure autonomic failure and multiple system atrophy? *Auton. Neurosci.* **2021**, *231*, 102773. [CrossRef] [PubMed]
39. Huang, C.C.; Lai, Y.R.; Lien, C.Y.; Cheng, B.C.; Tsai, N.W.; Lu, C.H. The role of electrochemical skin conductance as a screening test of cardiovascular autonomic neuropathy in patients with parkinson's disease. *Int. J. Environ. Res. Public Health* **2020**, *17*, 7751. [CrossRef]

40. Harms-Ringdahl, K.; Carlsson, A.M.; Ekholm, J.; Raustorp, A.; Svensson, T.; Toresson, H.G. Pain assessment with different intensity scales in response to loading of joint structures. *Pain* **1986**, *27*, 401–411. [CrossRef]

41. Ogon, M.; Krismer, M.; Sollner, W.; Kantner-Rumplmair, W.; Lampe, A. Chronic low back pain measurement with visual analogue scales in different settings. *Pain* **1996**, *64*, 425–428. [CrossRef]

42. Jensen, M.P.; Karoly, P.; Braver, S. The measurement of clinical pain intensity: A comparison of six methods. *Pain* **1986**, *27*, 117–126. [CrossRef]

43. Shafshak, T.S.; Elnemr, R. The visual analogue scale versus numerical rating scale in measuring pain severity and predicting disability in low back pain. *J. Clin. Rheumatol. Pract. Rep. Rheum. Musculoskelet. Dis.* **2020**. [CrossRef] [PubMed]

44. Harden, R.N.; Weinland, S.R.; Remble, T.A.; Houle, T.T.; Colio, S.; Steedman, S.; Kee, W.G.; American Pain Society Physicians. Medication quantification scale version III: Update in medication classes and revised detriment weights by survey of American Pain Society Physicians. *J. Pain Off. J. Am. Pain Soc.* **2005**, *6*, 364–371. [CrossRef]

45. Gallizzi, M.; Gagnon, C.; Harden, R.N.; Stanos, S.; Khan, A. Medication quantification scale version III: Internal validation of detriment weights using a chronic pain population. *Pain Pract.* **2008**, *8*, 1–4. [CrossRef] [PubMed]

46. Mayaudon, H.; Miloche, P.O.; Bauduceau, B. A new simple method for assessing sudomotor function: Relevance in type 2 diabetes. *Diabetes Metab.* **2010**, *36*, 450–454. [CrossRef]

47. Syngle, A.; Verma, I.; Garg, N.; Krishan, P. Autonomic dysfunction in psoriatic arthritis. *Clin. Rheumatol.* **2013**, *32*, 1059–1064. [CrossRef]

48. Vinik, A.I.; Smith, A.G.; Singleton, J.R.; Callaghan, B.; Freedman, B.I.; Tuomilehto, J.; Bordier, L.; Bauduceau, B.; Roche, F. Normative values for electrochemical skin conductances and impact of ethnicity on quantitative assessment of sudomotor function. *Diabetes Technol. Ther.* **2016**, *18*, 391–398. [CrossRef] [PubMed]

49. El-Badawy, M.A.; El Mikkawy, D.M. Sympathetic dysfunction in patients with chronic low back pain and failed back surgery syndrome. *Clin. J. Pain* **2016**, *32*, 226–231. [CrossRef] [PubMed]

50. Sahin, N.; Muslumanoglu, L.; Karatas, O.; Cakmak, A.; Ozcan, E.; Berker, E. Evaluation of sympathetic response in cases with failed back surgery syndrome. *Agri* **2009**, *21*, 10–15.

51. de Andrade, D.C.; Bendib, B.; Hattou, M.; Keravel, Y.; Nguyen, J.P.; Lefaucheur, J.P. Neurophysiological assessment of spinal cord stimulation in failed back surgery syndrome. *Pain* **2010**, *150*, 485–491. [CrossRef]

52. Pickering, G.; Achard, A.; Corriger, A.; Sickout-Arondo, S.; Macian, N.; Leray, V.; Lucchini, C.; Cardot, J.M.; Pereira, B. Electrochemical skin conductance and quantitative sensory testing on fibromyalgia. *Pain Pract.* **2020**, *20*, 348–356. [CrossRef]

53. Kapural, L.; Peterson, E.; Provenzano, D.A.; Staats, P. Clinical evidence for spinal cord stimulation for failed back surgery syndrome (FBSS): Systematic review. *Spine* **2017**, *42* (Suppl S14), S61–S66. [CrossRef]

54. Martinez-Martinez, L.A.; Mora, T.; Vargas, A.; Fuentes-Iniestra, M.; Martinez-Lavin, M. Sympathetic nervous system dysfunction in fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome, and interstitial cystitis: A review of case-control studies. *J. Clin. Rheumatol. Pract. Rep. Rheum. Musculoskelet. Dis.* **2014**, *20*, 146–150. [CrossRef]

55. Goudman, L.; Brouns, R.; Linderoth, B.; Moens, M. Effects of spinal cord stimulation on heart rate variability in patients with failed back surgery syndrome. *PLoS ONE* **2019**, *14*, e0219076. [CrossRef]

56. Goudman, L.; De Smedt, A.; Louis, F.; Stalmans, V.; Linderoth, B.; Rigoard, P.; Moens, M. The link between spinal cord stimulation and the parasympathetic nervous system in patients with failed back surgery syndrome. *Neuromodulation* **2021**. [CrossRef] [PubMed]

57. Anselmino, M.; Ravera, L.; De Luca, A.; Capriolo, M.; Bordese, R.; Trevi, G.P.; Grimaldi, R. Spinal cord stimulation and 30-min heart rate variability in refractory angina patients. *Pacing Clin. Electrophysiol. PACE* **2009**, *32*, 37–42. [CrossRef] [PubMed]

58. Moore, R.; Groves, D.; Nolan, J.; Scutt, D.; Pumpria, J.; Chester, M.R. Altered short term heart rate variability with spinal cord stimulation in chronic refractory angina: Evidence for the presence of procedure related cardiac sympathetic blockade. *Heart Br. Card. Soc.* **2004**, *90*, 211–212. [CrossRef]

59. Malliani, A.; Lombardi, F.; Pagani, M. Power spectrum analysis of heart rate variability: A tool to explore neural regulatory mechanisms. *Br. Heart J.* **1994**, *71*, 1–2. [CrossRef]

60. Wu, M.; Linderoth, B.; Foreman, R.D. Putative mechanisms behind effects of spinal cord stimulation on vascular diseases: A review of experimental studies. *Auton. Neurosci.* **2008**, *138*, 9–23. [CrossRef]

61. Waszak, P.M.; Modric, M.; Paturej, A.; Malyshev, S.M.; Przygocka, A.; Garnier, H.; Szmuda, T. Spinal cord stimulation in failed back surgery syndrome: Review of clinical use, quality of life and cost-effectiveness. *Asian Spine J.* **2016**, *10*, 1195–1204. [CrossRef]

62. LeDoux, M.S.; Langford, K.H. Spinal cord stimulation for the failed back syndrome. *Spine* **1993**, *18*, 191–194. [CrossRef] [PubMed]

63. Pope, J.E.; Deer, T.R.; Falowski, S.; Provenzano, D.; Hanes, M.; Hayek, S.M.; Amrani, J.; Carlson, J.; Skaribas, I.; Parchuri, K.; et al. Multicenter retrospective study of neurostimulation with exit of therapy by explant. *Neuromodulation* **2017**, *20*, 543–552. [CrossRef] [PubMed]

64. De Jaeger, M.; Goudman, L.; Putman, K.; De Smedt, A.; Rigoard, P.; Geens, W.; Moens, M. The added value of high dose spinal cord stimulation in patients with failed back surgery syndrome after conversion from standard spinal cord stimulation. *J. Clin. Med.* **2020**, *9*, 3126. [CrossRef]
65. Patel, S.K.; Gozal, Y.M.; Saleh, M.S.; Gibson, J.L.; Karsy, M.; Mandybur, G.T. Spinal cord stimulation failure: Evaluation of factors underlying hardware explantation. *J. Neurosurg. Spine* **2019**, *1–6*. [CrossRef]

66. Tronstad, C.; Johnsen, G.K.; Grimnes, S.; Martinsen, O.G. A study on electrode gels for skin conductance measurements. *Physiol. Meas.* **2010**, *31*, 1395–1410. [CrossRef]

67. Boucsein, W.; Fowles, D.C.; Grimnes, S.; Ben-Shakhar, G.; Roth, W.T.; Dawson, M.E.; Filion, D.L.; Society for Psychophysiological Research Ad Hoc Committee on Electrodermal Measures. Publication recommendations for electrodermal measurements. *Psychophysiology* **2012**, *49*, 1017–1034. [CrossRef]

68. Khadka, N.; Bikson, M. Role of skin tissue layers and ultra-structure in transcutaneous electrical stimulation including tDCS. *Phys. Med. Biol.* **2020**, *65*, 225018. [CrossRef]

69. Claeys, L.G.; Berg, W.; Jonas, S. Spinal cord stimulation in the treatment of chronic critical limb ischemia. *Acta Neurochir. Suppl.* **2007**, *97*, 259–265. [CrossRef]

70. Ather, M.; Di Vadi, P.; Light, D.; Wedley, J.R.; Hamann, W.C. Spinal cord stimulation does not change peripheral skin blood flow in patients with neuropathic pain. *Eur. J. Anaesthesiol.* **2003**, *20*, 736–739. [CrossRef]

71. Lobov, G.I.; Gerasimenko, Y.P.; Moshonkina, T.R. Mechanisms of blood flow regulation in the skin during stimulation of the spinal cord in humans. *Dokl. Biol. Sci.* **2019**, *485*, 27–29. [CrossRef]

72. Brown, R.; Macefield, V.G. Skin sympathetic nerve activity in humans during exposure to emotionally-charged images: Sex differences. *Front. Physiol.* **2014**, *5*, 111. [CrossRef] [PubMed]

73. Matsukawa, K.; Endo, K.; Ishii, K.; Ito, M.; Liang, N. Facial skin blood flow responses during exposures to emotionally charged movies. *J. Physiol. Sci.* **2018**, *68*, 175–190. [CrossRef]

74. Bari, D.S.; Aldosky, H.Y.Y.; Tronstad, C.; Kalvoy, H.; Martinsen, O.G. Influence of relative humidity on electrodermal levels and responses. *Skin Pharmacol. Physiol.* **2018**, *31*, 298–307. [CrossRef]

75. Ayoub, H.; LAIR, V.; Griveau, S.; Brunswick, P.; Bedioui, F.; Cassir, M. Electrochemical characterization of stainless steel as a new electrode material in a medical device for the diagnosis of sudomotor dysfunction. *Electroanalysis* **2012**, *24*, 1324. [CrossRef]

76. Bedioui, F.; Lair, V.; Griveau, S.; Ringuedé, A.; Zagal, J.H.; Cassir, M. Electrochemical behavior of electrode materials (nickel and stainless steels) for sudomotor dysfunction applications: A review. *Electroanalysis* **2018**, *30*, 2525–2534. [CrossRef]